logo
China pledges to crack down on illicit exports of rare earths, urges US to lift more trade controls

China pledges to crack down on illicit exports of rare earths, urges US to lift more trade controls

Washington Post18-07-2025
BANGKOK — China's state security agency says it is cracking down on alleged smuggling of rare earths minerals that it says threaten national security, just weeks after Beijing and Washington agreed to make it easier for American firms to obtain from China those materials, which are critical for manufacturing and computer chip production.
In a report published Friday in the state-run newspaper Global Times, the Ministry of State Security said foreign 'espionage and intelligence agencies' were colluding to steal rare earths-related goods by repackaging and relabeling rare metals to hide their Chinese origin.
In some cases the minerals were falsely declared as non-controlled items, mislabeled as such things as 'solder paste,' mixed into other materials like ceramic tiles, or hidden in plastic mannequins or bottled water, it said.
It referred only to an unnamed 'certain country' that it said lacked the capacity to make and refine its own rare earths.
Investigations had found Chinese criminals were involved, exploiting shipping and delivery channels to evade controls on exports of the materials used in many high-tech applications including electric vehicle batteries, it said.
The crackdown followed a report by Reuters earlier this month detailing how rare earths were being transshipped to the U.S. via Thailand and Mexico.
China is the main source for many strategically vital rare earths and it has moved to slow exports of such minerals in retaliation for steep import duties President Donald Trump has imposed on Chinese goods since he returned to the White House and launched his crusade to overturn a global trading system he says is unfair to the United States and its workers.
That followed an earlier series of restrictions by Beijing on exports of such materials as gallium, germanium, antimony and tungsten in response to trade friction with the administration of then-President Joe Biden.
In April, Beijing imposed permitting requirements on seven rare earth elements, under a Chinese law that applies to all exports, not just those bound for the U.S. market.
With the permitting process taking 45 days, the new requirement caused a pause in shipments, threatening to disrupt production of cars, robots, wind turbines and other high-tech products in the U.S. and around the world. The U.S., meanwhile, added to restrictions on exports of advanced technologies to China.
Rare earths have remained at the center of China-U.S. talks aimed at staving off huge tariff increases that were postponed in May to allow time for negotiations on a broader trade agreement. The deadline for reaching a deal is Aug. 12.
An agreement announced in late June did not remove China's permitting requirement on rare earths, but Beijing agreed to flexibility in dialing up or down the approval process as needed.
Computer chips are another key bone of contention.
The Chinese Commerce Ministry said Friday that it had taken note of a decision by the Trump administration to lift restrictions on exports of key semiconductors used in artificial intelligence made by Nvidia and its rival Advanced Micro Devices.
In April, the Trump administration announced it would restrict sales of Nvidia's H20 chips to China — as well as MI308 chips from AMD.
But Commerce Ministry spokesman Wang Wentao said restoring healthy trade ties will require more action by Washington.
U.S. export controls on Ascend chips made by Chinese tech giant Huawei Technologies have hurt the interests of Chinese companies, Wang told reporters in Beijing.
'We hope that the United States and China will meet each other halfway and correct their wrong practices through equal consultation, create a good environment for mutually beneficial cooperation between enterprises of both sides, and jointly maintain the stability of the global semiconductor production and supply chain,' he said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trump's EU Deal Could Cost Pharma Industry $19 Billion, Analyst Warns
Trump's EU Deal Could Cost Pharma Industry $19 Billion, Analyst Warns

Newsweek

timea few seconds ago

  • Newsweek

Trump's EU Deal Could Cost Pharma Industry $19 Billion, Analyst Warns

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The trade deal struck between the European Union and the United States over the weekend could cost the pharmaceutical industry billions, thanks to the 15 percent tariff rate applied to most goods under the terms of the agreement. Though the EU is set to invest hundreds of billions of dollars into the U.S. through energy purchases and other investments, pharmaceutical companies could incur additional expenses totaling $19 billion, according to Bernstein analyst Courtney Breen, cited by Reuters. Breen added that firms could mitigate some of these costs through inventory stockpiling and other strategies. Newsweek reached out to the Commerce Department and European Commission via email for comment. Why It Matters Pharmaceuticals were the fifth most imported product to the U.S. in 2024, according to the Observatory of Economic Complexity think tank, and EU member nations accounted for the lion's share of these. While certain aspects of the preliminary trade deal are yet to be finalized and remain subject to approval by European leaders, 15 percent tariffs could prove a significant challenge for companies reliant on imported European pharmaceuticals, while resulting in higher drug prices for U.S. consumers. This is in addition to the impact on European pharma firms, which are already bracing for the results of the ongoing Commerce Department investigation into whether imported pharmaceuticals constitute a threat to U.S. national security that justifies even more levies. What To Know The preliminary agreement between the U.S. and EU was unveiled during a meeting between President Donald Trump and European Commission President Ursula von der Leyen in Scotland on Sunday. The pair contradicted each other on the question of pharmaceuticals—the former saying these were exempt and the latter saying the opposite, resulting in differing reports on whether European drugs would be subject to the agreed 15-percent tariff rate. However, officials from both sides later confirmed the 15 percent rate on pharmaceutical imports, according to reports from Bloomberg and Reuters. In a subsequent press conference, von der Leyen said that the only exception for pharma products would be for "certain generics," without specifying what these would be. Main: President Donald Trump at a meeting with European Commission President Ursula von der Leyen in Turnberry, Scotland, on July 27, 2025. Inset: Stock image of medications. Main: President Donald Trump at a meeting with European Commission President Ursula von der Leyen in Turnberry, Scotland, on July 27, 2025. Inset: Stock image of medications. Frank May / Andrew Harnik/picture-alliance/dpa/AP Images / Getty Images Pharmaceutical firms are also bracing for the outcome of an ongoing investigation by the Commerce Department into the national security implications of America's medicine imports. This probe was launched in April by Commerce Secretary Howard Lutnick under Section 232 of the 1962 Trade Expansion Act. Should it conclude that pharmaceutical imports threaten U.S. security, this could result in import restrictions or a higher tariff regardless of Sunday's agreement with the EU. However, Reuters cited Wall Street analysts as saying that the investigation will not result in additional sectoral duties for the EU, though it noted that this aspect of the agreement remains unclear. According to Euronews, citing EU sources familiar with the matter, pharmaceuticals were technically excluded from Sunday's agreement, and any decision by Trump to impose or lessen tariffs on them would have to wait until after the investigation concludes. What People Are Saying European Commission Ursula von der Leyen, at a press conference: "It's agreed that we have 15 percent [tariffs] for pharmaceuticals. Whatever the decision later on is, of the president of the U.S., how to deal with pharmaceuticals in general globally, that's on a different sheet of paper." She said earlier that the 15 percent tariff rate is "a clear ceiling. So no stacking. All-inclusive." Kimberley Clausing, an economist and professor of Tax Law and Policy at UCLA School of Law, told Newsweek: "The United States is levying large new tariffs, so the United States consumers will suffer from larger tax increases than their European counterparts. But some European producers will also be harmed by reduced U.S. market access." "On net, the Europeans have the advantage, since they at least can maintain free and open trade with other partners while the United States is busy destroying the gains from trade with all of our trading partners." What Happens Next It is unclear when the results of the ongoing investigation into pharmaceutical imports might be made public.

Jim Cramer sees pockets of 'turmoil' in the market — plus, the latest on Nvidia's plans for China
Jim Cramer sees pockets of 'turmoil' in the market — plus, the latest on Nvidia's plans for China

CNBC

timea few seconds ago

  • CNBC

Jim Cramer sees pockets of 'turmoil' in the market — plus, the latest on Nvidia's plans for China

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. ET. Here's a recap of Tuesday's key moments. 1. Stocks were slightly lower Tuesday morning, giving up some of the modest gains seen earlier in the session. Even when the S & P 500 was in the green, Jim Cramer called out some "turmoil" underneath the hood of the market, particularly in the health-care sector. The biggest mover to the downside in that cohort is Novo Nordisk , with shares plunging more than 20% after the GLP-1 maker slashed its 2025 sales outlook. The company lowered growth expectations for Wegovy in the obesity market and for Ozempic in the diabetes market. Club holding Eli Lilly is down 4.3% in sympathy. We trimmed our position in the biopharma giant Tuesday to mitigate our risk ahead of Lilly's own earnings report next week. 2. Nvidia hit a 52-week high earlier in Tuesday's session on the back of a Reuters report that said the artificial intelligence leader has placed an order with Taiwan Semiconductor Manufacturing Co. for 300,000 of its made-for-China H20 chips. Earlier this month, the Trump administration reversed a ban imposed in April that prohibited sales of H20 chips to the Chinese market over national security concerns. The new orders with TSMC adds to the existing inventory of 600,000 to 700,000 H20 chips, Reuters reported. Elsewhere, fellow chipmakers Advanced Micro Devices and Club holding Broadcom were solidly higher, as earnings from the likes of Cadence Design Systems cast a positive due on the broader AI trade. 3. Coffee giant Starbucks reports its third quarter of fiscal 2025 after the bell Tuesday. We're hoping to see a boost in same-store sales in the locations where turnaround artist CEO Brian Niccol has rolled out his "Green Apron Service" model, a strategy aimed at enhancing the customer experience. We'd also like to see how the company's labor investments are helping business operations and what the plans for its growth China business. Jim said he's "still not expecting big stuff" this quarter given the company is still in the early stages of the turnaround . Starbucks shares, which have trailed the market this year, were down nearly 1% Tuesday. 4. Stocks covered in Tuesday's rapid fire at the end of the video were: Boeing , United Health , Procter & Gamble , Merck , and Cadence Design Systems. (Jim Cramer's Charitable Trust is long LLY, NVDA, SBUX. See here for a full list of the stocks.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.

Novo's new CEO faces sceptical investors with Wegovy US sales in focus
Novo's new CEO faces sceptical investors with Wegovy US sales in focus

Yahoo

time28 minutes ago

  • Yahoo

Novo's new CEO faces sceptical investors with Wegovy US sales in focus

By Maggie Fick and Jacob Gronholt-Pedersen LONDON (Reuters) -Novo Nordisk's new CEO Maziar Mike Doustdar has been handed the reins to turn around the Wegovy-making firm's flagging sales growth and sliding share price. He first will need to win over sceptical investors. Doustdar, an Iranian-born Austrian national who grew up in the United States, is a company man. He joined Novo in 1992 as an office clerk in Vienna, rising through the ranks to head all commercial units globally - minus the U.S. "The company needs to address recent market challenges with speed and ambition," Novo Nordisk Chair Helge Lund said in a statement on Tuesday. "Mike has a clear vision of how to unlock the full potential of the opportunities ahead." Investors aren't so sure, worried that Doustdar's lack of U.S. experience will hinder his ability to turn things around in Novo's top market and take the battle to tough U.S. rival Eli Lilly. Novo, which became Europe's most valuable listed firm after the launch of Wegovy in 2021, has seen its shares slump since mid last year, which led to the abrupt removal in May of CEO Lars Fruergaard Jorgensen. On Tuesday the shares plunged more than 20%, knocking some $70 billion off the group's market cap. "When the stock falls as much as it has, people want to see change," said Barclays analyst Emily Field, adding that her sense was that "people are not happy" with the choice of CEO because it was not a big enough renewal. "My understanding is that he has never had U.S. operational experience, and the U.S. is all that matters." Novo - once worth as much as $615 billion, and now nearer $240 billion - has faced rising competition and been hit by copycat rivals to its weight-loss drugs, especially in the critical U.S. market, which led to a sharp profit warning earlier on Tuesday. In early calls with analysts and journalists, Doustdar said that there was an "urgency" to do things differently. "I don't like it," Doustdar said when asked about the share price plunge. "I don't like it as an employee, I don't like it as a CEO-elect, and I certainly don't like it as a shareholder myself. But setbacks don't define companies. Our response does." Jefferies analysts said they were surprised by the appointment of Doustdar, noting that feedback had suggested a preference for an external candidate. "I don't see this as super positive," said Lukas Leu, portfolio manager at Bellevue Asset Management, a Novo shareholder. Markus Manns, a portfolio manager at another shareholder, Union Investment, added there was "slight disappointment". "People had hoped for an external candidate," he said. Board chair Lund said external and internal candidates had been considered in the CEO search, and Doustdar had emerged as the leading candidate in part because he knows the company and its strengths and weaknesses. "He can respond and take actions on those, I think, quicker than anyone could do coming from the outside," Lund said.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store